Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021
February 01 2021 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or transection
to peripheral nerves, today confirmed that it will report fourth
quarter and full-year 2020 financial results on Monday, February
22, 2021 after the market closes. Axogen management will host an
investment-community conference call and webcast following the
release at 4:30 p.m. ET.
Investors interested in participating in the conference call by
phone may do so by dialing toll free at (877) 407-0993 or use the
direct dial-in number at (201) 689-8795. Those interested in
listening to the conference call live via the Internet may do so by
visiting the Investors page of the company's website
at www.axogeninc.com and clicking on the
webcast link.
Following the conference call, a replay will be available in the
Investors section of the company's website at
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. Axogen employees are passionate about helping to
restore peripheral nerve function and quality of life to patients
with physical damage or transection to peripheral nerves by
providing innovative, clinically proven and economically effective
repair solutions for surgeons and health care providers. Peripheral
nerves provide the pathways for both motor and sensory signals
throughout the body. Every day, people suffer traumatic injuries or
undergo surgical procedures that impact the function of their
peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; Axoguard® Nerve Cap, a
porcine submucosa ECM product used to protect a peripheral nerve
end and separate the nerve from the surrounding environment to
reduce the development of symptomatic or painful neuroma; and
Avive® Soft Tissue Membrane, a processed human umbilical cord
intended for surgical use as a resorbable soft tissue barrier. The
Axogen portfolio of products is available in the United States,
Canada, the United Kingdom, South Korea, and several other European
and international countries.
Contact:Axogen, Inc.Peter Mariani, Chief Financial
OfficerInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024